参考文献/References:
[1] 周自强,胡大一,陈捷, 等.中国心房颤动现状的流行病学研究[J].中华内科杂志, 2004,43(7):491-494.
[2] Wolf PA, Dawber TR, Thomas HE Jr, et al.Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study[J].Neurology,1978,28(10):973-977.
[3] Brignole M, Auricchio A, Baron-Esquivias G, et al.2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology(ESC).Developed in collaboration with the European Heart Rhythm Association(EHRA)[J].Europace,2013,15(8):1070-1118.
[4] January CT, Wann LS, Alpert JS, et al.2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society[J].J Am Coll Cardiol,2014,64(21): e1-e76.
[5] 胡大一,郭艺芳.心房颤动抗凝治疗中国专家共识[J].心脑血管病防治,2012,12(3):173-177.
[6] Hart RG, Pearce LA, Aguilar MI.Meta-analysis:antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation[J].Ann Intern Med,2007,146(12):857-867.
[7] Connolly S, Pogue J, Hart R, et al.Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events(ACTIVE W): a randomised controlled trial[J].Lancet,2006,367(9526):1903-1912.
[8] Mant J, Hobbs FD, Fletcher K, et al.Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation(the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial[J].Lancet,2007,370(9586):493-503.
[9] van Walraven C, Hart RG, Connolly S, et al.Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators[J].Stroke,2009,40(4):1410-1416.
[10] Patrono C, Coller B, FitzGerald GA, et al.Platelet-active drugs: the relationships among dose, effectiveness, and side effects:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[J].Chest, 2004,126(3 Suppl):234S-264S.
[11] CAPRIE Steering Committee.A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events(CAPRIE).CAPRIE Steering Committee[J].Lancet,1996,348(9038):1329-1339.
[12] Connolly SJ, Pogue J, Hart RG, et al.Effect of clopidogrel added to aspirin in patients with atrial fibrillation[J].N Engl J Med,2009,360(20):2066-2078.
[13] Connolly SJ, Ezekowitz MD, Yusuf S, et al.Dabigatran versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2009,361(12):1139-1151.
[14] Eikelboom JW, Wallentin L, Connolly SJ, et al.Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation:an analysis of the randomized evaluation of long-term anticoagulant therapy(RE-LY)trial[J].Circulation,2011,123(21):2363-2372.
[15] Hori M, Connolly SJ, Zhu J, et al.Dabigatran versus warfarin:effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation[J].Stroke,2013,44(7):1891-1896.
[16] Patel MR, Mahaffey KW, Garg J, et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J].N Engl J Med,2011,365(10):883-891.
[17] Halperin JL, Hankey GJ, Wojdyla DM, et al.Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation(ROCKET AF)[J].Circulation,2014,130(2):138-146.
[18] Wong KS, Hu DY, Oomman A, et al.Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial[J].Stroke,2014,45(6):1739-1747.
[19] Diener HC, Eikelboom J, Connolly SJ, et al.Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack:a predefined subgroup analysis from AVERROES, a randomised trial[J].Lancet Neurol,2012,11(3):225-231.
[20] Granger CB, Alexander JH, McMurray JJ, et al.Apixaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2011,365(11):981-992.
[21] Lopes RD, Al-Khatib SM, Wallentin L, et al.Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation:a secondary analysis of a randomised controlled trial[J].Lancet,2012,380(9855):1749-1758.
[22] Giugliano RP, Ruff CT, Braunwald E, et al.Edoxaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2013,369(22):2093-2104.
[23] Miller CS, Grandi SM, Shimony A, et al.Meta-analysis of efficacy and safety of new oral anticoagulants(dabigatran, rivaroxaban, apixaban)versus warfarin in patients with atrial fibrillation[J].Am J Cardiol, 2012,110(3):453-460.
[24] Chatterjee S, Sardar P, Biondi-Zoccai G, et al.New oral anticoagulants and the risk of intracranial hemorrhage:traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation[J].JAMA Neurol,2013,70(12):1486-1490.
[25] Ruff CT, Giugliano RP, Braunwald E, et al.Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation:a meta-analysis of randomised trials[J].Lancet,2014,383(9921):955-962.
[26] Saliba W.Non-vitamin K antagonist oral anticoagulants:new choices for patient management in atrial fibrillation[J].Am J Cardiovasc Drugs,2015,15(5):323-335.
[27] Loffredo L, Perri L, Violi F.Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation:a meta-analysis of interventional trials[J].Dig Liver Dis,2015,47(5):429-431.
[28] Rasmussen LH, Larsen TB, Graungaard T, et al.Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation:indirect comparison analysis[J].BMJ,2012,345:e7097.
[29] Harel Z, Sholzberg M, Shah PS, et al.Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD[J].J Am Soc Nephrol,2014,25(3):431-442.
[30] Eikelboom JW, Connolly SJ, Brueckmann M, et al.Dabigatran versus warfarin in patients with mechanical heart valves[J].N Engl J Med,2013,369(13):1206-1214.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(2):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(2):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]张源,王群山.达比加群酯在器质性心脏病的心房颤动中的应用进展[J].心血管病学进展,2016,(1):27.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.008]
ZHANG Yuan,WANG Qunshan.Advance of Research about Dabigatran Etexliate in
Organic Heart Disease with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(2):27.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.008]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(2):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(2):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(2):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(2):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(2):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(2):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
[11]蒋靖波,钟国强.心房颤动导管消融中脑卒中和无症状脑梗死的预防[J].心血管病学进展,2015,(6):743.[doi:10.3969/j.issn.1004-3934.2015.06.022]
JIANG Jingbo,ZHONG Guoqiang.Strategies to Prevent Periprocedural Stroke and Subclinical Cerebral Emboli in
Patients Undergoing Catheter Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(2):743.[doi:10.3969/j.issn.1004-3934.2015.06.022]